Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Leiomyoma 2 cyclopia sequence 1 Vomiting 1 Urinary Bladder Neoplasms 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Pain 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Nausea 1 Myasthenia Gravis 1 Melanoma 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma 1 Lung Neoplasms 1 Lower Urinary Tract Symptoms 1 Insulin Resistance 1 Infertility 1 Hyperandrogenism 1 Hot Flashes 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Diarrhea 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 51 Ipilimumab 50 Cyclophosphamide 43 Nivolumab 41 aldesleukin 30 Interleukin-2 23 Vemurafenib 20 fludarabine 19 Temozolomide 18 fludarabine phosphate 15 dabrafenib 15 trametinib 12 spartalizumab 10 Radiotherapy 10 Radiosurgery 10 Dacarbazine 10 CTLA-4 Antigen 10 cobimetinib 9 binimetinib 9 poly ICLC 7 encorafenib 7 Paclitaxel 7 atezolizumab 6 Introns 6 Biopsy 6 montanide ISA 51 5 Carboplatin 5 epacadostat 4 MART-1 Antigen 4 Interferon alpha-2 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × Sugars × Clear all

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Dana-Farber Cancer Institute

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡